Analysis
US IPO listings reached 238 through the first days of September 2026, up 3.48% from the same point last year, according to data cited by StockAnalysis' 2026 IPO tracker and Renaissance Capital's pricing calendar. The count is the highest year-to-date total since 2021's IPO boom, but it obscures a market that is arguably more concentrated at the top than that headline number suggests.
Consider the two largest deals of the year: SpaceX's June IPO alone raised $75 billion at a $1.77 trillion valuation -- the biggest IPO in history, more than triple Alibaba's prior US record -- and Cerebras' May debut raised $5.5 billion before its stock popped to a roughly $95 billion market cap on day one.
Those two listings combined likely exceed the total proceeds of the other 236 IPOs on the list, a pattern consistent across recent cycles: overall count recovers faster than overall depth, because a handful of mega-caps can lift the count's optics without lifting the market for mid-sized issuers.
What the count doesn't show
Oura's pending listing, targeting up to $3 billion at a $16 billion-plus valuation, and Crusoe's private $30 billion valuation ahead of a rumored IPO both sit in the AI-adjacent cluster now dominating institutional allocation conversations.
Traditional software and biotech IPO candidates -- categories that drove 2021's count -- are comparatively scarce in 2026's pipeline, a rotation that matters more for where LP dollars ultimately land than the topline 238 figure does on its own.
